

NeuroSearch A/S
Pederstrupvej 93
DK - 2750 Ballerup
Denmark
Telephone: +45 4460 8000
Telefax: +45 4460 8080
ns@neurosearch.dk
www.neurosearch.com
CVR No: DK-12 54 61 06

Announcement

Notice concerning release date for the NeuroSearch financial statements 2007

The NeuroSearch A/S (NEUR.CO) annual report 2006 will be on the agenda of the board meeting scheduled for 5 March 2007 and the financial statements will be released on the same day.

A teleconference will be held on 5 March 2007 at 3 pm Copenhagen time (2 pm London time, 9 am New York time). Flemming Pedersen, CEO, Anita Milland, Vice President, CFO and Hanne Leth Hillman, Vice President, Director of IR & Corporate Communications, will present the annual report and answer questions. The telephone conference will be conducted in English and the telephone number is +44 (0)20 7162 0125. The corresponding PowerPoint presentation will be available via www.neurosearch.com.

Asger Aamund
Chairman of the Board

Contact person: Hanne Leth Hillman, Vice President,
Director of IR & Corporate Communications

Telephone: +45 4460 8212 or +45 4017 5103

StockWise summary:

The NeuroSearch annual report 2006 will be on the agenda of the board meeting scheduled for 5 March 2007. The financial statements will be released on the same day and a teleconference will be held at 3 pm Copenhagen time (2 pm London time, 9 am New York time).

NeuroSearch is a Scandinavian biopharmaceutical company listed on the Copenhagen Stock Exchange (NEUR). Our core business covers the development of novel drugs, based on a broad and well-established drug discovery platform focusing on ion channels and transporters. A substantial part of the company's activities are partner financed through a broad alliance with GlaxoSmithKline (GSK) and collaborations with among others Abbott and Astellas. Eight drug programmes are in clinical development: ACR16 for the treatment of Huntington's disease (under preparation for Phase III), tesofensine for the treatment of obesity/type 2 diabetes (Phase II), NS2359 for the treatment of depression (Phase II) and ADHD (Phase II) in partnership with GSK, NS1209 for the treatment of epilepsy and pain (Phase II), ABT-894 for pain treatment (Phase I) in partnership with Abbott, ACR16 for the treatment of schizophrenia (Phase I) in partnership with Astellas, and ACR325 for the treatment of psychoses such as bipolar disorder (Phase I). In addition, NeuroSearch has a broad portfolio of preclinical drug candidates and has equity interests in several biotech companies.